Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs

Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and the Covid vaccine.

Pfizer said it recorded a $5.6 billion charge for inventory write-offs in the third quarter due to lower-than-expected use of Covid products. Of these previously announced write-offs, $4.7 billion is chalked up to Paxlovid and $900 million is attributed to the company’s vaccine.

The pharmaceutical giant also reiterated the full-year adjusted earnings and revenue guidance it announced two weeks ago, which is drastically lower than its initial projections due to weakening demand for its Covid products. That decline in demand also led Pfizer to announce a sweeping $3.5 billion cost-cutting plan at the same time. 

Those efforts were seen as necessary to shore up investor sentiment as Pfizer and its rivals such as Moderna struggle to navigate the rapid decline of their Covid businesses, which are transitioning to the commercial market in the U.S. this year.

Here’s what Pfizer reported for the third quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

• Loss per share: 17 cents, adjusted vs. 34 cents expected
• Revenue: $13.23 billion vs. $13.34 billion expected

Pfizer’s stock fell more than 2% in morning trading Tuesday. Shares of Pfizer were down roughly 40% for the year through Monday’s close, putting the company’s market value at around $172.5 billion.

Pfizer reported third-quarter revenue of $13.23 billion, down 42% from the same period a year ago, due to the decline in sales of its Covid products.

The company’s Covid vaccine raked in $1.31 billion in sales, down 70% from the year-ago quarter. Analysts had expected the shot to bring in $1.53 billion in sales, according to FactSet estimates.

Paxlovid posted $202 million in revenue, a drop of 97%. Analysts had expected $613.5 million in sales of the drug, according to FactSet estimates.

Together, the products pulled in around $1.5 billion in revenue for the quarter. That compares with roughly $12 billion in sales during the same period a year ago.

For the third quarter, Pfizer booked a net loss of $2.38 billion, or 42 cents per share. That compares to a net income of $8.61 billion, or $1.51 per share, during the same period a year ago. 

Excluding certain items, the company’s loss per share was 17 cents for the quarter. The inventory write-offs of Covid products accounted for an 84 cent per share adjusted loss, Pfizer CFO David Denton said during an earnings call on Tuesday.

Pfizer reiterated the guidance it outlined in October: The company expects 2023 sales of $58 billion to $61 billion and full-year adjusted earnings of $1.45 to $1.65 per share.

The company anticipates that its Covid vaccine will rake in $11.5 billion in sales this year.

Meanwhile, the pharmaceutical giant expects its Covid antiviral treatment Paxlovid to bring in $1 billion in revenue. Pfizer has agreed to take eight million Paxlovid courses back early from the U.S. government, which is part of an effort to get more higher-priced sales of the drug on the commercial market.

Eliquis, which is marketed in partnership with Bristol Myers Squibb, is among the first 10 drugs to face Medicare drug price negotiations.

Wells Fargo analyst Mohit Bansal said in a research note Tuesday that the operational revenue growth during the quarter “bodes well” for Pfizer to meet its full-year guidance of 6% to 8% growth for non-Covid products compared to 2022. 

The company had a busy few months of product launches, which included a vaccine for RSV, an ulcerative colitis pill, a meningococcal vaccine and of course, the newest version of its Covid vaccine. That brings Pfizer to 13 out of 19 planned product launches.

Among the six remaining product launches is Pfizer’s experimental flu vaccine, which it expects to launch after 2024. The company on Tuesday announced that its shot achieved positive initial results when compared to a currently marketed flu vaccine in an ongoing late-stage trial on people ages 18 to 64.

But investors are still waiting for more data on Pfizer’s flu vaccine in adults 65 and older. People 65 years and older are at higher risk of developing serious complications from flu, compared with young, healthy adults. Between 70% and 85% of seasonal flu-related deaths in the U.S. occurred among people 65 years and older in recent years, according to the Centers for Disease Control and Prevention.

Investors are also waiting for updates on a midstage trial of Pfizer’s oral obesity pill danuglipron, which could potentially compete with Eli Lilly‘s experimental obesity pill orforglipron. Positive data could solidify Pfizer as a viable competitor in the weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated.

Pfizer executives said that the company expects to close its $43 billion acquisition of cancer therapy maker Seagen in late 2023 or early 2024, subject to customary closing conditions such as clearance by the Federal Trade Commission.

The European Commission, the executive body of the European Union, already approved the proposed buyout earlier this month.

Pfizer continues to believe the deal could contribute more than $10 billion in risk-adjusted sales by 2030. 

Don’t miss these CNBC PRO stories: